Open

Relapsed Peripheral T-cell Lymphoma Treatment Study

In this study, we want to find out if a new drug called Soquelitinib (also known as CPI-818) can be safely given to people. We are also checking to see if it can help treat a type of cancer called relapsed peripheral T-cell lymphoma (PTCL).

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

The study involves medical history, questions about you, questionnaires, physical examination, MRI, CT/PET scan, photographs of your skin, urine and blood tests, ECG, tumor assessments and biopsies, and study drugs. Reimbursement provided.

Incentives

study medication; lodging, meals, parking, mileage reimbursement

In-person visits:
0 - 30 times

Phone or online visits:
0 - 10 times

Total length of participation:
36 months

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with Peripheral T-cell lymphoma (PTCL), which could be PTCL-NOS, follicular helper T-cell lymphoma (FHTCL), or systemic anaplastic large-cell lymphoma (sALCL)
Your cancer has either progressed, relapsed, or cannot tolerate standard of care treatment and have had one line of treatment for your cancer

Not eligible if:

You have T-cell Lymphoma with active central nervous system involvement
You have received an allogeneic stem cell transplant or are a candidate for stem cell transplant at study screening
You have a history of primary immunodeficiency or solid organ transplantation
You have an active infection requiring IV therapy
You are unable to swallow or absorb oral medications

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Comprehensive Cancer Center
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Anne Beaven
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Lymphoma)

IRB Number

24-1765

ClinicalTrials.gov

NCT06561048

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.